A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

310

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Crohn's Disease
Interventions
BIOLOGICAL

Certolizumab Pegol (CDP870)

"Liquid for subcutaneous injection, 200 mg/ml. 400 mg at Weeks 0, 2, 4 and thereafter every 4 weeks until Week 360.~Up to 84 months of therapy in this study."

Trial Locations (141)

Unknown

45102, Birmingham

45028, Huntsville

45044, Little Rock

45095, Orange

45101, San Francisco

45130, Colorado Springs

45094, Gainesville

45005, Hialeah

45087, Miami

45004, North Miami Beach

45016, Chicago

45037, Indianapolis

45019, Lexington

45033, Chevy Chase

45013, Laurel

45083, Rochester

45108, Jefferson City

45035, Berlin

45009, Great Neck

45070, New York

45145, Greenville

45067, High Point

45003, Raleigh

45040, Winston-Salem

45081, Cincinnati

45091, Cincinnati

45054, Dayton

45025, Mayfield Heights

45039, Oklahoma City

45041, Tulsa

45093, Hershey

45113, Germantown

45119, Nashville

45022, Houston

45073, San Antonio

45139, Salt Lake City

45052, South Ogden

45134, Charlottesville

45078, Christiansburg

45109, Norfolk

45141, Seattle

11011, Bankstown

11005, New Lambton

11017, Herston

11006, South Brisbane

11014, Lauceston

11016, Ballarat

11007, Box Hill

11002, Fitzroy

11013, Frankston

11012, Parkville

11009, Adelaide

11010, Fremantle

11015, Garran

11018, Newtown

46006, Linz

46003, Salzburg

46002, Vienna

12001, Minsk

13004, Brussels

13001, Ghent

13003, Leuven

15001, Sofia

16005, Winnipeg

16014, Halifax

16013, Toronto

16008, Montreal

18006, Hradek Kralove

18001, Ostrava

18002, Prague

18004, Prague

19004, Aalborg

19009, Copenhagen

19010, Herlev

19007, Hvidovre

19003, Vejle

20001, Tallinn

20002, Tartu

22002, Berlin

22009, Berlin

22004, Celle

22019, Frankfurt

22013, Göttingen

22017, Hanover

22015, Kiel

22016, Leipzig

22001, Minden

22012, Munich

22008, Münster

24002, Budapest

24009, Pécs

24011, Szekszárd

26004, Beersheba

26007, Haifa

26005, Petha Tikva

27001, Milan

27004, Palermo

27007, Roma

31002, Auckland

31001, Christchurch

31005, Hamilton

31004, Milford

31003, Tauranga

32005, Oslo

32008, Oslo

32004, Tromsø

33008, Bydgoszcz

33003, Gdansk

33018, Lublin

33013, Szczecin

33007, Warsaw

33009, Warsaw

34017, Lipetsk

34006, Moscow

34016, Nizhny Novgorod

34001, Saint Petersburg

34005, Saint Petersburg

34007, Saint Petersburg

34013, Saint Petersburg

35001, Belgrade

35002, Belgrade

35004, Belgrade

36002, Singapore

38001, Celje

38003, Ljubljana

39013, Johannesburg

39003, Cape Town

39016, Cape Town

39018, Cape Town

39012, Goodwood

39010, Johannesburg

39008, Midrand

39004, Port Elizabeth

39006, Pretoria

39009, Pretoria

39014, Pretoria

39019, Pretoria

40009, Barcelona

43008, Dniepropetrovsk

43003, Lviv

43006, Odesa

All Listed Sponsors
lead

UCB Pharma SA

INDUSTRY

NCT00160706 - A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease | Biotech Hunter | Biotech Hunter